Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

This study is testing a new drug called LNS8801, alone or combined with an immunotherapy drug called pembrolizumab, in people with advanced or metastatic solid tumors or lymphoma that have not responded to other treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced or metastatic solid tumor or lymphoma that has progressed despite other treatments - Depending on the study group, you may need to have specific cancer types (e.g., melanoma, pancreatic, lung, colorectal, uveal melanoma, or breast cancer) or have previously received immunotherapy (PD-1/PD-L1 drugs) - You have adequate organ function (blood counts, kidney, liver) - You are willing and able to take oral capsules/tablets **You may NOT be eligible if...** - You have thyroid or gallbladder cancer (for early-phase groups only) - Your cancer is known to be estrogen receptor positive - You are currently on estrogen hormone replacement therapy or have estrogen-sensitive cancer - You have active autoimmune disease requiring treatment - You are HIV positive, have active hepatitis B or C - You are pregnant, breastfeeding, or have been pregnant within the last 2 years - You have severe heart problems or a history of serious immune-related side effects from prior immunotherapy Talk to your doctor to see if this trial is right for you.